Tonix Pharmaceuticals (TNXP) Competitors $0.14 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TNXP vs. PRPH, BYSI, VTGN, ALRN, CMRX, IKNA, CASI, PMVP, OVID, and JATTShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include ProPhase Labs (PRPH), BeyondSpring (BYSI), Vistagen Therapeutics (VTGN), Aileron Therapeutics (ALRN), Chimerix (CMRX), Ikena Oncology (IKNA), CASI Pharmaceuticals (CASI), PMV Pharmaceuticals (PMVP), Ovid Therapeutics (OVID), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. ProPhase Labs BeyondSpring Vistagen Therapeutics Aileron Therapeutics Chimerix Ikena Oncology CASI Pharmaceuticals PMV Pharmaceuticals Ovid Therapeutics JATT Acquisition Tonix Pharmaceuticals (NASDAQ:TNXP) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Which has more volatility and risk, TNXP or PRPH? Tonix Pharmaceuticals has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Which has higher earnings and valuation, TNXP or PRPH? ProPhase Labs has higher revenue and earnings than Tonix Pharmaceuticals. ProPhase Labs is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$12.46M1.54-$116.66M-$110.970.00ProPhase Labs$17.97M2.30-$16.78M-$1.21-1.79 Does the media favor TNXP or PRPH? In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than ProPhase Labs. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 0 mentions for ProPhase Labs. Tonix Pharmaceuticals' average media sentiment score of 0.00 beat ProPhase Labs' score of -0.07 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Tonix Pharmaceuticals Neutral ProPhase Labs Neutral Do analysts rate TNXP or PRPH? Tonix Pharmaceuticals presently has a consensus price target of $53.50, indicating a potential upside of 38,114.29%. ProPhase Labs has a consensus price target of $11.00, indicating a potential upside of 409.26%. Given Tonix Pharmaceuticals' higher possible upside, equities analysts clearly believe Tonix Pharmaceuticals is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in TNXP or PRPH? 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 20.7% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is TNXP or PRPH more profitable? ProPhase Labs has a net margin of -146.39% compared to Tonix Pharmaceuticals' net margin of -1,196.11%. ProPhase Labs' return on equity of -54.04% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,196.11% -158.27% -119.36% ProPhase Labs -146.39%-54.04%-28.65% Does the MarketBeat Community prefer TNXP or PRPH? Tonix Pharmaceuticals received 226 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 62.16% of users gave Tonix Pharmaceuticals an outperform vote while only 50.00% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34062.16% Underperform Votes20737.84% ProPhase LabsOutperform Votes11450.00% Underperform Votes11450.00% SummaryTonix Pharmaceuticals beats ProPhase Labs on 9 of the 17 factors compared between the two stocks. Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.22M$6.74B$5.02B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio0.0011.77128.7716.66Price / Sales1.54291.011,724.9679.31Price / CashN/A46.0936.9133.53Price / Book0.005.304.605.19Net Income-$116.66M$150.82M$114.09M$223.67M7 Day Performance-21.79%-0.82%110.41%2.70%1 Month Performance0.43%15.17%124.29%8.76%1 Year Performance-99.14%36.66%154.67%28.76% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals3.1918 of 5 stars$0.14flat$53.50+37,629.2%-99.1%$19.46M$12.46M0.00103Gap UpPRPHProPhase Labs3.0501 of 5 stars$2.27+0.9%$11.00+384.6%-52.9%$43.31M$44.38M-1.88130Positive NewsGap UpBYSIBeyondSpringN/A$2.17-2.3%N/A+139.8%$84.69M$1.88M0.0080Positive NewsVTGNVistagen Therapeutics2.5085 of 5 stars$3.09+1.3%$13.50+336.9%-7.2%$83.51M$971,000.00-2.0940Upcoming EarningsHigh Trading VolumeALRNAileron Therapeutics3.8178 of 5 stars$3.85-5.6%$19.00+393.5%+244.8%$83.22MN/A-1.189Positive NewsHigh Trading VolumeCMRXChimerix4.3321 of 5 stars$0.92-1.1%$8.50+823.9%-6.6%$82.46M$144,000.00-0.9772Upcoming EarningsIKNAIkena Oncology3.0461 of 5 stars$1.70-0.6%$3.00+76.5%-60.9%$82.04M$1.84M-1.2070Positive NewsCASICASI Pharmaceuticals3.0805 of 5 stars$6.12-0.2%$6.00-2.0%+26.5%$82.01M$23.10M-3.01180Gap DownPMVPPMV Pharmaceuticals2.7127 of 5 stars$1.59-3.6%$5.75+261.6%-14.7%$81.92MN/A-1.6450OVIDOvid Therapeutics4.4162 of 5 stars$1.15-3.4%$4.04+251.3%-68.1%$81.62M$390,000.00-2.6760Positive NewsJATTJATT AcquisitionN/A$4.63+3.3%N/A-10.2%$79.87MN/A0.003Gap UpHigh Trading Volume Related Companies and Tools Related Companies ProPhase Labs Alternatives BeyondSpring Alternatives Vistagen Therapeutics Alternatives Aileron Therapeutics Alternatives Chimerix Alternatives Ikena Oncology Alternatives CASI Pharmaceuticals Alternatives PMV Pharmaceuticals Alternatives Ovid Therapeutics Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TNXP) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
